Tourette's Syndrome Clinical Trial
Official title:
Effects of Lactobacillus Plantarum PS128 in Patients With Tourette's Syndrome
To evaluate whether supplementing with PS128 can improve the symptoms and quality of life related to Tourette's disease in children.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 4 Years to 18 Years |
Eligibility | Inclusion Criteria: - Age 4-18 years old - Tourette's disease is diagnosed - Make sure it is not caused by medication or other diseases - Cause major interference in social interaction, study or work - The healthy control group is not diagnosed with Tourette's disease, and is judged by PI Exclusion Criteria: - Have taken antibiotics within a month or are receiving antibiotic treatment - Used probiotic products in powder, capsule or tablet form within two weeks (except yogurt, yogurt, Yakult and other related foods) - Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy) - Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis - Those with a history of cancer - Those who are allergic to lactic acid bacteria products - Those who are not suitable to participate judged by PI |
Country | Name | City | State |
---|---|---|---|
Taiwan | China Medical University Hospital | Taichung |
Lead Sponsor | Collaborator |
---|---|
China Medical University Hospital | Bened Biomedical Co., Ltd. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Yale Global Tic Severity Scale (YGTSS) | The YGTSS scale refers to Yale Global Tic Severity Scale, and it is a rating tool used to gauge the course of Tourette's syndrome in patients. | From Baseline to 12 Weeks Assessed | |
Secondary | Beck Youth Inventories (BYI-II) | The new Beck Youth Inventories™ Second Edition (BYI-2) uses five self-report inventories to assess symptoms of depression, anxiety, anger, disruptive behavior, and self-concept in children and adolescents. | From Baseline to 12 Weeks Assessed | |
Secondary | Attention-Deficit/Hyperactivity Disorder Test (ADHDT) | The test yields standard scores, percentile ranks, severity levels, and probability of ADHD. | From Baseline to 12 Weeks Assessed | |
Secondary | Child Behavior Checklist (CBCL) | The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. It is widely used in both research and clinical practice with youths. | From Baseline to 12 Weeks Assessed | |
Secondary | Autism Behavior Checklist-Taiwan Version (ABCT) | The Autism Behavior Checklist (ABC) is one component of the Autism Screening Instrument for Educational Planning (ASIEP) and is the only one that has been evaluated psychometrically. The ABC is a 57-item behavior rating scale assessing the behaviors and symptoms of autism for children 3 and older. | From Baseline to 12 Weeks Assessed | |
Secondary | Visual Analogue Scale for GI symptoms (VAS-GI) | Visual Analogue Scale for GI symptoms, VAS-GI (visual analogue scale, VAS 0-10) was designed to measure the response of symptoms and well-being in patients after taking PS128. | From Baseline to 12 Weeks Assessed | |
Secondary | Gilles de la Tourette Syndrome-Quality of Life Scale (GTS-QOL) | The Gilles de la Tourette Syndrome-Quality of Life Scale (GTS-QOL) is a self-rated disease-specific questionnaire to assess health-related quality of life of subjects with GTS. | From Baseline to 12 Weeks Assessed | |
Secondary | Gut microbiota | Intestinal microbiota may contribute to the metabolic health of the human host and, when aberrant, to the pathogenesis of various common metabolic disorders including obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases and malnutrition. | From Baseline to 12 Weeks Assessed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00965211 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome
|
N/A | |
Recruiting |
NCT00152750 -
Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD
|
Phase 4 | |
Completed |
NCT00241176 -
Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
|
Phase 4 | |
Terminated |
NCT00226824 -
Safety Study of Galantamine in Tic Disorders
|
Phase 4 | |
Completed |
NCT01244633 -
Ecopipam Treatment of Tourette Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT00026000 -
Brain Activation in Vocal and Motor Tics
|
N/A | |
Terminated |
NCT00001260 -
Brain Tissue Collection for Neuropathological Studies
|
||
Completed |
NCT02102698 -
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
|
Phase 2 | |
Withdrawn |
NCT02112253 -
Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01133353 -
A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome
|
Phase 2 | |
Completed |
NCT02205918 -
Brain-Behavior Interactions in Tic Suppression
|
||
Terminated |
NCT00282139 -
Aripiprazole in the Treatment of Tourette's Syndrome
|
N/A | |
Completed |
NCT03042507 -
Psychosocial Intervention for Young Children With Chronic Tics
|
N/A | |
Completed |
NCT01019343 -
Physiological Investigations of Movement Disorders
|
N/A | |
Completed |
NCT02619084 -
Subthalamic Stimulation in Tourette's Syndrome
|
Phase 2 | |
Completed |
NCT00368433 -
Hypersensitivity in Tourette Syndrome
|
N/A | |
Withdrawn |
NCT01475383 -
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06361004 -
Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome
|
N/A | |
Completed |
NCT00139308 -
High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome
|
Phase 1 |